

A Recovery Fellowship for Healthcare Professionals and Their Loved Ones

Donate Now





Hello,

We are excited to announce that each week leading up to the 76th Annual Conference in Spokane, WA, we will be highlighting one of our esteemed CE (Continuing Education) speakers! This week, we're thrilled to shine the spotlight on **Steve Klein**, who will be sharing his expertise on **GLP-1 Inhibitors for the Treatment of Addiction**.

Dr. Steve Klein is a physician and researcher specializing in medical genetics and addiction medicine. He is currently completing a fellowship in Addiction Medicine at Caron Treatment Centers and Tower Health, with a focus on integrating his expertise to treat adolescents with substance use disorders. Dr. Klein trained in Pediatrics and Medical Genetics at the Children's Hospital of Philadelphia (CHOP) after earning his MD-PhD at UCLA-Caltech, where he specialized in human genetics. His research explores methylation and stress responses in the heritability of addiction, as well as novel applications of GLP-1 receptor agonists in substance use disorders. Board-certified in Pediatrics and eligible in Medical Genetics, Dr. Klein is licensed in Pennsylvania and holds a DEA registration. He is actively involved in professional advocacy, serving as Board Member and Membership Committee Chair for IDAA. To learn more about Steve and find out when he will be presenting as part of our our 2025 agenda, [Click Here].

The objectives of the Steve's CE presentation are outlined below:

Understand the Neurobiology of Addiction and Reward Pathways

- Describe the role of dopamine and other neurotransmitters in addiction and reward regulation.
- Explain how neuroadaptations in the brain contribute to substance use disorders (SUDs) and compulsive behaviors.

Explore the Mechanisms of GLP-1R Agonists in the Brain

- Summarize the physiological role of glucagon-like peptide-1 (GLP-1) in metabolism and appetite regulation.
- Discuss emerging evidence on GLP-1 receptor expression in the brain and its impact on reward processing, cravings, and impulse control.

Evaluate the Evidence for GLP-1R Agonists in Treating Addiction

- Review preclinical and clinical studies on the efficacy of GLP-1R agonists in reducing substance use (e.g., alcohol, nicotine, opioids, stimulants).
- Compare GLP-1R agonists with current pharmacological treatments for addiction, identifying potential advantages and limitations.

Identify Clinical Applications and Future Directions

- Discuss the potential integration of GLP-1R agonists into addiction treatment protocols, including patient selection and dosing considerations.
- Recognize gaps in research and the need for further clinical trials to establish safety, efficacy, and long-term outcomes.

Stay tuned as we introduce additional CE speakers in the coming weeks. Our CE credits are approved by the appropriate accrediting bodies and can help you meet licensure and certification requirements. **Click here** to see the types of CE credits that are available. Our 2025 CE Accreditation Statement can be found **here**.

We can't wait to see you at the conference!Register Here!


Yours in Service, Michael M. & Newaj A. - Spokane CE Co-Chairs

Register for Spokane

Get In Touch

IDAA 5123 W 98th St., #1110,

Contact Us



IDAA | 5123 W 98th St. #1110 | Minneapolis, MN 55437 US

Unsubscribe | Constant Contact Data Notice



Try email marketing for free today!